Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

Contact:Joshua T. Brumm
Executive Vice President, Finance
Phone: 408-215-3311

Ramses Erdtmann
Vice President of Investor Relations
Phone: 408-215-3325Pharmacyclics, Inc.
Condensed Consolidated Balance Sheets
(unaudited; in thousands)

 December 31,June 30, 20122012AssetsCash, cash equivalents and marketable securities 1

$
317,114$
203,607Other current assets 2

29,3789,788Total current assets

346,492213,395Property and equipment, net

6,4033,842Other assets

2,2341,883Total assets

$
355,129$
219,120Liabilities and Stockholders' EquityDeferred revenue - current portion

$
8,139$
8,054Other current liabilities

21,11810,932Total current liabilities

29,25718,986Deferred revenue - non-current portion

62,56267,324Deferred rent

784687Total liabilities

92,60386,997Stockholders' equity

262,526132,123Total liabilities and stockholders' equity

$
355,129$
219,1201Marketable securities

$
9,681$
5,7112As of December 31, 2012 and June 30, 2012, Other current assets includes $26.6 million and $5.8 million, respectively, due to t
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... NEW YORK , March 31, ... ), a biopharmaceutical company advancing protein biologic therapies ... its Korean marketing partner, Hanmi Pharmaceutical Co., Ltd ... Korea from the country,s Ministry of Food and ... Research Institute (KTR) for MuGard, its oncology supportive-care ...
(Date:3/31/2015)... Lighthouse Information Systems, Inc., a West ... Oregon, Washington and clients across the US, announces ... (M&A) Integration Services offering, effective immediately. ... M&A Integration Practice Leader at Lighthouse, explains, “Research ... M&A initiatives fail to achieve their intended economic ...
(Date:3/30/2015)... , March 30, 2015  NuGene International, ... subsidiary corporation, NuGene BioPharma, Inc. has added another ... Dr. Guan is an internationally recognized researcher ... his college education at Peking University, ... degree from the University of North Carolina, Chapel ...
(Date:3/30/2015)... Md. , March 30, 2015    ... leader in synthetic biology, and Merck Serono, the ... Germany , today announced an exclusive strategic ... Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This ... develop innovative therapies that modulate the immune system,s ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Lighthouse Information Systems, Inc., Announces Addition of M&A Integration Services 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4
... A. How is fold amplification , ... using the Van Gelder and Eberwine ... an oligo(dT) primer containing the T7 RNA polymerase , ... at the end of mRNA sequences serves as the substrate for the , ...
... , Quantitate gene ... 5 minute cell lysis , ... monitoring , siRNA-induced knockdown , ... Gene Expression Assays and SYBR Green , ...
... , , ... and validation Screening for miRNAs that regulate target , ... cellular process , ... RNAs that are expressed in animals and plants and affect the , ...
Cached Biology Technology:RNA Amplification for Array Analysis 2RNA Amplification for Array Analysis 3RNA Amplification for Array Analysis 4Ready for Real-time in 5 Minutes 2Ready for Real-time in 5 Minutes 3Ready for Real-time in 5 Minutes 4Ready for Real-time in 5 Minutes 5Ready for Real-time in 5 Minutes 6Precursor miRNAs for Successful miRNA Functional Studies 2Precursor miRNAs for Successful miRNA Functional Studies 3Precursor miRNAs for Successful miRNA Functional Studies 4Precursor miRNAs for Successful miRNA Functional Studies 5Precursor miRNAs for Successful miRNA Functional Studies 6Precursor miRNAs for Successful miRNA Functional Studies 7Precursor miRNAs for Successful miRNA Functional Studies 8Precursor miRNAs for Successful miRNA Functional Studies 9Precursor miRNAs for Successful miRNA Functional Studies 10Precursor miRNAs for Successful miRNA Functional Studies 11
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Levanger, Norway and Boulder, CO, USA -- April 10, ... a new collaboration to advance the clinical use of ... of biomarkers for the prediction of cardiovascular events such ... collaboration will analyze biological samples and clinical data from ...
... N.M. An air sampler the size of an ear ... to improve computer climate models. "We now have an ... said Sandia National Laboratories researcher Ron Manginell, lead author of ... , the often-cited journal of the American Institute of Physics. ...
... Alzheimer,s disease (AD) is now the sixth leading cause of death ... of 65. There is currently no treatment that alters the course ... changes in the way the body handles iron and other metals ... AD symptoms. A new study shows that reducing iron levels in ...
Cached Biology News:Miniature Sandia sensors may advance climate studies 2Miniature Sandia sensors may advance climate studies 3Miniature Sandia sensors may advance climate studies 4Miniature Sandia sensors may advance climate studies 5Antioxidant may disrupt Alzheimer's disease process 2
Request Info...
These macrocarriers are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 macrocarriers....
... [pTyr 209/ pSer 211 ] affinity isolated ... Dulbecco's phosphate buffered saline (without Mg 2+ ... mg/ml BSA (IgG and protease free) and 0.05% ... the region of mouse Hck that contains tyrosine ...
High voltage electrophoresis power supply...
Biology Products: